Given the growing interest in developing MCL1-targeted therapies for cancers, such as acute myeloid leukemia and breast cancer [46], RPS4X could represent an upstream regulatory factor worth targeting to overcome apoptotic resistance. This evidence concerns the gene MCL1 and breast cancer.